Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01077310 · ClinicalTrials.gov registry record · NA
Alcohol Pharmacotherapy for HIV+ Prisoners
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT01077310 is a NA study that has completed, run by Yale University. The registered enrollment target is 100 participants.
The verdict
NCT01077310, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
This is a randomized controlled trial of injectable intramuscular naltrexone (XR-NTX) versus intramuscular placebo among HIV-infected prisoners meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for alcohol dependence or problem drinking, who are transitioning to the community and seeking treatment to prevent relapse to alcohol use. We hypothesize that extended release naltrexone (XR-NTX) will result in improved HIV outcomes (lower log10 HIV-1RNA levels and higher CD4 count) as well as improved alcohol treatment outcomes, and reduced drug/sex HIV related risk behaviors and decreased rates of reincarceration.
Interventions
- DRUG Placebo
- DRUG Vivitrol- Intramuscular naltrexone (depot-formulation)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2010-08 |
| Est. Completion | 2015-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01077310
The ClinicalTrials.gov registry entry for NCT01077310 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01077310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01077310 about?
NCT01077310 is a clinical study titled "Alcohol Pharmacotherapy for HIV+ Prisoners". This is a randomized controlled trial of injectable intramuscular naltrexone (XR-NTX) versus intramuscular placebo among HIV-infected prisoners meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for alcohol dependence or problem drinking, who are transiti...
What is the current status of trial NCT01077310?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2010-08. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01077310?
The interventions under investigation include: Placebo (DRUG), Vivitrol- Intramuscular naltrexone (depot-formulation) (DRUG).
Who is sponsoring clinical trial NCT01077310?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.